Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30003409 | 1.00 | KCNJ1 (0.61) | KCNJ1KDM4EPOLBMAPTKMT2A | |
| SCHEMBL600130 | 0.86 | MAPT (0.64) | KCNJ1KDM4EPOLBMAPTKMT2A | |
| SCHEMBL5717534 | 0.84 | MAPT (0.59) | KCNJ1KDM4EPOLBMAPTKMT2A | |
| SCHEMBL354153 | 0.84 | KDM4E (0.66) | KCNJ1KDM4EPOLBMAPTKMT2A | |
| SCHEMBL26971044 | 0.84 | MAPT (0.65) | KDM4EPOLBMAPTKMT2AMEN1 | |
| SCHEMBL14376686 | 0.81 | MAPT (0.58) | KCNJ1KDM4EPOLBMAPTKMT2A | |
| SCHEMBL3358083 | 0.77 | KCNJ1 (0.57) | KCNJ1KDM4EMAPTKMT2AHTT | |
| SCHEMBL16897509 | 0.76 | KCNJ1 (1.00) | KCNJ1KMT2AALDH1A1LMNA | |
| SCHEMBL1612695 | 0.76 | MEN1 (0.51) | KCNJ1KDM4EPOLBMAPTKMT2A | |
| SCHEMBL1612693 | 0.76 | MEN1 (0.51) | KCNJ1KDM4EPOLBMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287070-A1 | FUSED HETEROCYCLIC DERIVATIVES | JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) | 2024-08-29 | — | — | US | disclosed |
| CN-117999075-A | Compounds and pharmaceutical compositions comprising inhibitors of amyloid peptide interaction with glycosaminoglycans, methods of treatment, and uses thereof | 吉斯莫治疗股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| WO-2022253259-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-12-08 | — | — | WO | disclosed |
| EP-2725027-B1 | NOVEL COMPOUND WITH AMYLOID AFFINITY | NIHON MEDIPHYSICS CO LTD (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-9211350-B2 | Compound with amyloid affinity | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2015-12-15 | — | — | US | disclosed |
| US-9211350-B2 | Compound with amyloid affinity | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2015-12-15 | — | — | US | disclosed |
| US-8952175-B2 | Method for production of 3-hydroxypropan-1-one compound, method for production of 2-propen-1-one compound and method for production of isoxazoline compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-02-10 | — | — | US | disclosed |
| US-20140121377-A1 | NOVEL COMPOUND WITH AMYLOID AFFINITY | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2014-05-01 | — | — | US | disclosed |
| EP-2725027-A1 | NOVEL COMPOUND WITH AMYLOID AFFINITY | Nihon Medi-Physics Co., Ltd. (JP) | 2014-04-30 | — | — | EP | disclosed |
| CN-103596950-A | Novel compound with amyloid affinity | NIHON MEDIPHYSICS CO LTD | 2014-02-19 | — | — | CN | disclosed |
| WO-2012176587-A1 | NOVEL COMPOUND WITH AMYLOID AFFINITY | 日本メジフィジックス株式会社 (JP) | 2012-12-27 | — | — | WO | disclosed |
| US-20100137612-A1 | METHOD FOR PRODUCTION OF 3-HYDROXYPROPAN-1-ONE COMPOUND FOR PRODUCTION OF 2- PROPEN-1-ONE COMPOUND AND METHOD FOR PRODUCTION OF ISOXAZLINE COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137612-A1 | METHOD FOR PRODUCTION OF 3-HYDROXYPROPAN-1-ONE COMPOUND FOR PRODUCTION OF 2- PROPEN-1-ONE COMPOUND AND METHOD FOR PRODUCTION OF ISOXAZLINE COMPOUND | ADH1C, CYP2E1, ADH1A | KCNJ1 268/4885KDM4E 3628/4885POLB 1538/4885 |
| US-20240287070-A1 | FUSED HETEROCYCLIC DERIVATIVES | HAVCR2, HCCS, GOT2 | KCNJ1 4552/4885KDM4E 3515/4885POLB 587/4885 |
| US-20140121377-A1 | NOVEL COMPOUND WITH AMYLOID AFFINITY | APP, APBA1, BACE1 | KCNJ1 2075/4885KDM4E 4344/4885POLB 4541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.